Amicus Therapeutics, Inc. (FOLD): Price and Financial Metrics

Amicus Therapeutics, Inc. (FOLD): $11.03

1.13 (-9.29%)

POWR Rating

Component Grades








Add FOLD to Watchlist
Sign Up

Industry: Biotech




#33 of 356

in industry

FOLD Price/Volume Stats

Current price $11.03 52-week high $14.10
Prev. close $12.16 52-week low $9.10
Day low $10.94 Volume 3,598,100
Day high $12.16 Avg. volume 2,383,865
50-day MA $12.89 Dividend yield N/A
200-day MA $12.34 Market Cap 3.17B

FOLD Stock Price Chart Interactive Chart >


  • FOLD scores best on the Growth dimension, with a Growth rank ahead of 95.36% of US stocks.
  • FOLD's strongest trending metric is Stability; it's been moving down over the last 177 days.
  • FOLD ranks lowest in Sentiment; there it ranks in the 6th percentile.

FOLD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FOLD is 3.14 -- better than 82.95% of US stocks.
  • FOLD's price/sales ratio is 10.04; that's higher than the P/S ratio of 90.46% of US stocks.
  • The volatility of AMICUS THERAPEUTICS INC's share price is greater than that of merely 14.52% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to FOLD, based on their financial statements, market capitalization, and price volatility, are QUIK, KIND, LITE, IVAC, and ORGN.
  • FOLD's SEC filings can be seen here. And to visit AMICUS THERAPEUTICS INC's official web site, go to

FOLD Valuation Summary

  • FOLD's EV/EBIT ratio is -25.4; this is 318.97% lower than that of the median Healthcare stock.
  • Over the past 199 months, FOLD's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for FOLD.

Stock Date P/S P/B P/E EV/EBIT
FOLD 2023-09-22 10.0 31.5 -19.0 -25.4
FOLD 2023-09-21 10.0 31.4 -18.9 -25.3
FOLD 2023-09-20 10.1 31.7 -19.1 -25.5
FOLD 2023-09-19 10.6 33.2 -20.0 -26.6
FOLD 2023-09-18 10.5 33.1 -20.0 -26.6
FOLD 2023-09-15 10.7 33.7 -20.3 -27.0

FOLD Growth Metrics

    Its 2 year price growth rate is now at -42%.
  • Its 4 year net cashflow from operations growth rate is now at -80.01%.
  • The 5 year price growth rate now stands at 74.74%.
FOLD's revenue has moved up $41,468,000 over the prior 15 months.

The table below shows FOLD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 323.291 -156.317 -263.98
2022-06-30 321.145 -168.391 -280.988
2022-03-31 317.827 -188.452 -270.056
2021-12-31 305.514 -202.491 -250.46
2021-09-30 293.931 -181.799 -238.584
2021-06-30 281.823 -200.107 -252.301

FOLD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FOLD has a Quality Grade of C, ranking ahead of 63.39% of graded US stocks.
  • FOLD's asset turnover comes in at 0.333 -- ranking 138th of 680 Pharmaceutical Products stocks.
  • RDUS, CLVS, and NSTG are the stocks whose asset turnover ratios are most correlated with FOLD.

The table below shows FOLD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.333 0.884 -0.273
2021-03-31 0.323 0.884 -0.312
2020-12-31 0.323 0.881 -0.383
2020-09-30 0.308 0.884 -0.458
2020-06-30 0.286 0.886 -0.501
2020-03-31 0.246 0.883 -0.524

FOLD Price Target

For more insight on analysts targets of FOLD, see our FOLD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.90 Average Broker Recommendation 1.64 (Moderate Buy)

Amicus Therapeutics, Inc. (FOLD) Company Bio

Amicus Therapeutics is developing treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey.

FOLD Latest News Stream

Event/Time News Detail
Loading, please wait...

FOLD Latest Social Stream

Loading social stream, please wait...

View Full FOLD Social Stream

Latest FOLD News From Around the Web

Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Yahoo | September 29, 2023

UPDATE 1-US FDA approves Amicus Therapeutics' muscle disorder treatment

Amicus Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a muscle disorder called Pompe disease. The health regulator last October extended its review for a second time following delays in inspections caused by pandemic-related travel restrictions. The therapy is indicated for use in adults living with late-onset Pompe disease and those without an improvement on their current enzyme replacement therapy, the company said.

Yahoo | September 28, 2023

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

Pombiliti + Opfolda Logo Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today at 12:00 p.m. ET PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (migl

Yahoo | September 28, 2023

Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark

Amicus Therapeutics just cleared that benchmark with an upgrade from 77 to 82. Amicus Therapeutics is trying to complete a consolidation with a 14.10 buy point. Amicus Therapeutics earns the No. 39 rank among its peers in the Medical-Biomed/Biotech industry group.

Yahoo | September 28, 2023 featured highlights include Amicus Therapeutics, Genius Sports and Viad

Amicus Therapeutics, Genius Sports and Viad are part of the Zacks Screen of the Week article.

Yahoo | September 21, 2023

Read More 'FOLD' Stories Here

FOLD Price Returns

1-mo -14.63%
3-mo N/A
6-mo -0.27%
1-year 5.65%
3-year -18.11%
5-year -15.80%
YTD -9.66%
2022 5.71%
2021 -49.98%
2020 137.06%
2019 1.67%
2018 -33.43%

Continue Researching FOLD

Here are a few links from around the web to help you further your research on Amicus Therapeutics Inc's stock as an investment opportunity:

Amicus Therapeutics Inc (FOLD) Stock Price | Nasdaq
Amicus Therapeutics Inc (FOLD) Stock Quote, History and News - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!